In this study, we report on the development and preclinical evaluation of CD19-ReTARGTPR, a novel fusion protein that selectively binds to CD19-expressing cancer cells, resulting in their rapid elimination by pre-existing anti-CMVpp65 CTLs via physiological TCR/pHLA engagement. This evidence concerns the gene CD19 and cancer.